Closing the translation gap in oncology drug development
Drug Discovery World
MAY 9, 2023
Fewer than 5% of oncology drugs that enter clinical trials in the US receive US FDA approval. This abysmal success rate significantly trails the overall approval rate for compounds entering human trials (about 10% of which reach commercialisation). Cancer is far more complex than the sum of its parts.
Let's personalize your content